Form 4: Halozyme Therapeutics Director Akiko Moni Miyashita Reports Stock and Option Grant

Director Akiko Moni Miyashita reports acquisition of Halozyme Therapeutics stock and options as part of the director compensation program.

Summary

• Akiko Moni Miyashita, a director of Halozyme Therapeutics, reported a transaction on April 25, 2024.
• The transaction involved the acquisition of 6,501 shares of common stock and an option to purchase 8,804 shares of common stock.
• The common stock was acquired through a restricted stock unit (RSU) grant under the issuer's director compensation program.
• The option was granted under the issuer's director compensation program with an exercise price of $38.46.
• Both the RSU and option grants will vest in full on the earlier of April 25, 2025, or the date of the Issuer's next annual meeting of stockholders.
• Following the reported transactions, Miyashita beneficially owns 20,772 shares of common stock and options to purchase 8,804 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard director compensation practices, aligning interests with shareholders.

Positives

• The director's acquisition of stock and options aligns her interests with those of the shareholders.
• The vesting schedule encourages long-term commitment to the company's success.

Future Outlook

The director's compensation structure is designed to incentivize long-term value creation for shareholders.

Industry Context

Director compensation packages often include stock and option grants to align management's interests with those of shareholders, promoting long-term growth and value.

Comparison to Industry Standards

• Director compensation packages in the biotechnology industry commonly include a mix of cash, stock options, and restricted stock units.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar compensation structures to incentivize their directors.
• The vesting schedules are typically aligned with industry standards, encouraging long-term commitment and value creation.

Stakeholder Impact

• Shareholders: Aligns director's interests with shareholder value.
• Employees: Reinforces the company's commitment to incentivizing key personnel.
• Company: Supports long-term strategic goals through incentivized leadership.

Key Dates